Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Amortizatization of Intangibles (2020 - 2025)

Historic Amortizatization of Intangibles for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $1.0 million.

  • Lyell Immunopharma's Amortizatization of Intangibles fell 7187.06% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 5454.3%. This contributed to the annual value of $14.7 million for FY2024, which is 5299.08% up from last year.
  • Lyell Immunopharma's Amortizatization of Intangibles amounted to $1.0 million in Q3 2025, which was down 7187.06% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Amortizatization of Intangibles ranged from a high of $4.4 million in Q1 2024 and a low of -$552000.0 during Q3 2021
  • For the 5-year period, Lyell Immunopharma's Amortizatization of Intangibles averaged around $1.4 million, with its median value being $1.2 million (2022).
  • As far as peak fluctuations go, Lyell Immunopharma's Amortizatization of Intangibles tumbled by 19837.84% in 2021, and later skyrocketed by 99826.84% in 2023.
  • Quarter analysis of 5 years shows Lyell Immunopharma's Amortizatization of Intangibles stood at -$467000.0 in 2021, then surged by 358.67% to $1.2 million in 2022, then surged by 180.13% to $3.4 million in 2023, then fell by 12.38% to $3.0 million in 2024, then crashed by 65.97% to $1.0 million in 2025.
  • Its Amortizatization of Intangibles was $1.0 million in Q3 2025, compared to $1.2 million in Q2 2025 and $1.7 million in Q1 2025.